Back to Search Start Over

Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylorivaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial

Authors :
Zeng, Ming
Mao, Xu-Hu
Li, Jing-Xin
Tong, Wen-De
Wang, Bin
Zhang, Yi-Ju
Guo, Gang
Zhao, Zhi-Jing
Li, Liang
Wu, De-Lin
Lu, Dong-Shui
Tan, Zhong-Ming
Liang, Hao-Yu
Wu, Chao
Li, Da-Han
Luo, Ping
Zeng, Hao
Zhang, Wei-Jun
Zhang, Jin-Yu
Guo, Bo-Tao
Zhu, Feng-Cai
Zou, Quan-Ming
Source :
The Lancet; October 2015, Vol. 386 Issue: 10002 p1457-1464, 8p
Publication Year :
2015

Abstract

Helicobacter pyloriis one of the most common gastric pathogens, affecting at least half the world's population, and is strongly associated with gastritis, peptic ulcer, gastric adenocarcinoma, and lymphoma. We aimed to assess the efficacy, safety, and immunogenicity of a three-dose oral recombinant H pylorivaccine in children in China.

Details

Language :
English
ISSN :
01406736 and 1474547X
Volume :
386
Issue :
10002
Database :
Supplemental Index
Journal :
The Lancet
Publication Type :
Periodical
Accession number :
ejs36273322
Full Text :
https://doi.org/10.1016/S0140-6736(15)60310-5